We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eleven Biotherapeutics, Inc.today announced that the company has completed enrollment in the VISTA Phase 3 registration trial of Vicinium™ in patients with non-muscle invasive bladder cancer